8-K: Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK for Dystrophic Epidermolysis Bullosa Treatment

Krystal Biotech's VYJUVEK receives a positive recommendation from the European Medicines Agency's CHMP for treating dystrophic epidermolysis bullosa, paving the way for potential EU approval.

Summary

• Krystal Biotech has received a positive recommendation from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for VYJUVEK (beremagene geperpavec-svdt) to treat wounds in patients with dystrophic epidermolysis bullosa (DEB).
• The CHMP's recommendation supports the use of VYJUVEK in healthcare settings or at home, administered by healthcare professionals, trained patients, or caregivers.
• The final decision from the European Commission (EC) is expected in the second quarter of 2025 and will apply to all European Union member states, as well as Iceland, Norway, and Liechtenstein.
• The positive opinion is based on data from Phase 1/2 GEM-1 and Phase 3 GEM-3 studies, demonstrating successful COL7A1 gene delivery and durable wound closure.
• VYJUVEK was approved in the United States by the FDA in May 2023 for treating wounds in DEB patients six months and older.
• Krystal Biotech plans to launch VYJUVEK in Germany around the middle of 2025, followed by a launch in France later in the year.

Sentiment

Score: 9

Explanation: The document conveys a highly positive sentiment due to the positive CHMP opinion, which significantly increases the likelihood of European approval and market expansion for VYJUVEK. The management's comments and the anticipation of upcoming launches further contribute to the optimistic outlook.

Positives

• VYJUVEK is the first treatment that corrects the genetic defect in DEB patients.
• The treatment promotes durable wound closure.
• The CHMP supports a broad label, including treatment of patients from birth and at-home administration.
• The company is on track to launch in Germany around the middle of 2025.
• VYJUVEK has already been approved in the United States.

Risks

• The European Commission's final approval is still pending.
• Forward-looking statements are subject to various risks and uncertainties, as detailed in the company's SEC filings.

Future Outlook

Krystal Biotech anticipates the European Commission's approval of VYJUVEK and plans to launch the product in Germany around the middle of 2025, followed by a launch in France later in the year. The company aims to expand access to VYJUVEK for DEB patients across Europe.

Management Comments

• 'We are excited to be able to provide DEB patients with the first treatment that corrects the genetic defect and makes a true difference in their lives,' said Cristina Has, M.D., Professor and Head of the Genodermatoses Clinic in the Department of Dermatology at the University of Freiburg in Germany.
• 'We are very pleased that our patients, from birth, will have a simple, topical treatment that promotes durable wound closure, something that until now has been beyond the reach of any therapy,' added Christine Bodemer, M.D., PhD, Professor and Head of the Department of Dermatology at the Necker Enfants Malades Hospital in Paris.
• Suma Krishnan, President of Research and Development at Krystal Biotech, stated that the CHMPs recommendation is an exciting step towards delivering the first corrective therapy to DEB patients across Europe.
• Laurent Goux, Senior Vice President and General Manager of Europe at Krystal Biotech, mentioned that the team is preparing for Krystal's first commercial launch outside of the United States and remains on track to launch in Germany around the middle of 2025.

Industry Context

This announcement positions Krystal Biotech as a leader in the development of gene therapies for rare diseases, specifically dystrophic epidermolysis bullosa. The potential approval of VYJUVEK in Europe would expand the availability of this innovative treatment to a broader patient population, potentially setting a new standard of care.

Comparison to Industry Standards

• VYJUVEK's approach of delivering the COL7A1 gene directly to the wounds is a novel method compared to traditional wound care treatments.
• Other companies like Abeona Therapeutics and Castle Creek Biosciences are also developing therapies for DEB, but VYJUVEK is the first redosable gene therapy approved for this condition in the US.
• The positive CHMP opinion suggests that VYJUVEK's clinical data is compelling and meets the regulatory standards for approval in Europe, potentially giving it a competitive edge over other investigational therapies.

Stakeholder Impact

• DEB patients and their families will benefit from the potential availability of a new treatment option.
• Healthcare professionals will have a new tool for managing DEB wounds.
• Krystal Biotech's shareholders may see increased value due to the potential market expansion.
• Employees of Krystal Biotech will be involved in the commercialization and distribution of VYJUVEK in Europe.

Next Steps

• The European Commission will make a final decision on the approval of VYJUVEK.
• Krystal Biotech will prepare for the commercial launch of VYJUVEK in Germany around the middle of 2025.
• The company will also plan for a launch in France later in 2025.
• Krystal Biotech will continue to advance its pipeline of investigational genetic medicines.

Key Dates